News Hub | News Direct

All Industries


Article thumbnail News Release

Flash Secures $85 Million to Back Special Purpose Vehicle to Propel Growth and Provide Flexible Payment Options

Flash

Flash, the industry-leading end-to-end parking technology platform, today announced that it has closed on $85 million in debt financing for a newly formed special purpose vehicle (“SPV”) to accelerate platform adoption and offer Flash clients an expanded range of flexible payment options. The debt capital, which can be increased up to $100 million, was provided by Vantage Infrastructure (“Vantage”), a leading independent specialist infrastructure credit fund. “Asset owners and operators have a myriad of budgetary and deployment preferences – the payment options we can now extend through the SPV will allow customers to join the Flash platform on terms that work best for them," said Chris Donus, President of Flash. “Innovation in payment options is as critical as platform innovation in pursuit of our vision for the parking industry’s transformation in light of the scale and momentum we're on pace to achieve." Flash’s payment options allow clients to select amongst flexible monthly payment plans that suit their budgets, regardless of scale, asset type, or configuration. This includes EV charging infrastructure and other advanced parking technologies offered by Flash. Flash anticipates extending the SPV structure and partnership with Vantage in future financings. ”We’re pleased to support Flash with a tailored financing solution that enables their team to continue to meet and exceed their clients’ need for better transport related infrastructure,” said Nick Cleary, Senior Partner at Vantage. “This is a great example of the opportunity to upgrade and transform proven traditional infrastructure that saves time and costs for drivers and help build out the EV charging network.” Evercore acted as Flash’s exclusive financial advisor, and Cadwalader, Wickersham & Taft LLP provided legal counsel to Flash. Steptoe LLP acted as counsel to Vantage. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. About Vantage Infrastructure Vantage Infrastructure is an independent infrastructure specialist manager committed to delivering sustainable investment solutions with an equity and debt infrastructure investment portfolio of over US $4 billion invested in infrastructure assets across Europe, North America, and Australia on behalf of global clients. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 09, 2024 09:00 AM Central Daylight Time

Article thumbnail News Release

No More Wisdom Teeth Horror Stories? TriAgenics' Alternative To Painful Wisdom Teeth Removal

Benzinga

By Mangeet Kaur Bouns, Benzinga For countless people, the prospect of wisdom teeth removal stirs a deep sense of dread. While many undergo the procedure without incident, the reality is that this “routine” surgery is fraught with risks that can turn a simple operation into a painful and protracted ordeal. Complications are not just possible – they’re common. Dry sockets, for example, occur when the blood clot that forms after extraction becomes dislodged, exposing the underlying bone and nerves. The pain from a dry socket can be intense – often radiating to the ear – and it can take weeks for full recovery. Nearly 30% of patients experience bleeding, which, if not properly managed, can lead to further complications. Nerve damage, though less frequent, can result in permanent changes in sensation, affecting the lower lip, chin and gums. Even more concerning are the cases where wisdom teeth removal leads to life-threatening outcomes. The tragic story of 17-year-old Jenny Olenick, who suffered fatal brain damage due to oxygen deprivation while under anesthesia for a wisdom tooth extraction, serves as a somber reminder that no surgery is ever truly routine. Despite the best efforts of medical professionals, Jenny’s surgery ended in tragedy, a stark example of the potential dangers inherent in this common procedure. Complications Beyond The Expected: A Risky Rite Of Passage While stories like Jenny Olenick’s are rare, they highlight the unpredictable nature of wisdom teeth removal. What starts as a straightforward procedure can quickly spiral into a series of complications that demand additional medical intervention, prolong recovery and increase costs. For many patients, the aftermath of surgery is marked by a litany of issues: swelling, pain and difficulty opening the mouth are common, sometimes persisting for weeks. Trismus, a condition characterized by painful jaw movement, is particularly prevalent among younger patients, especially those between the ages of 17 and 25. This condition can make it challenging to perform everyday activities such as eating and speaking, further complicating the recovery process. Infections are another frequent concern, often manifesting as persistent discomfort, swelling and, in severe cases, fever or yellow discharge from the extraction site. If left untreated, these infections can lead to more serious complications, requiring antibiotics or even additional surgery. Sinus complications can occur in cases where the upper wisdom teeth are involved, adding another layer of risk. If the tooth roots are close to the sinus cavity, the removal can create an opening between the tooth socket and the sinus. This condition, known as sinus communication, can cause ongoing discomfort and complicate the healing process. Anesthesia reactions, although rare, pose their own risks, ranging from mild nausea to severe allergic reactions. In extreme cases, these reactions can be life-threatening. Such incidents, while uncommon, underscore the need for thorough preparation and careful monitoring during any surgical procedure. Given these risks, there is a clear unmet need for a safer, more reliable alternative to traditional wisdom teeth removal practices. Triagenics And Zero3 TBA: A Game-Changing Solution? Enter TriAgenics, a company potentially on the cusp of revolutionizing dental care with its innovative Zero3 Tooth Bud Ablation (TBA) technology. This procedure promises a potential end to the painful and often risky process of wisdom teeth removal by preventing wisdom teeth from forming in the first place. Zero3 TBA treatment is designed for children ages 6 to 12, a time when the early signs of wisdom teeth can be detected. The procedure is minimally invasive and highly precise, targeting and neutralizing the developing tooth bud tissue before it can grow into problematic third molars. TriAgenics reports that the entire process takes only 60 to 90 seconds per tooth bud, with the full treatment, which involves four tooth buds, completed in about 30 minutes. The company says that what makes Zero3 TBA particularly compelling is the simplicity and effectiveness of the procedure. Traditional wisdom teeth extraction involves cutting into the gums and bone to remove the teeth, which often leads to significant pain and a lengthy recovery period. Zero3 TBA is quick, minimally invasive and comes with minimal recovery time. The procedure’s targeted approach means that the risks of complications such as dry socket, nerve damage and infection are significantly reduced if not entirely eliminated, says TriAgenics. Disrupting A Multi-Billion Dollar Market The potential market for TriAgenics’ Zero3 TBA technology is large. With approximately 85% of all wisdom teeth eventually requiring removal, the demand for a preventative solution is clear. The company estimates that its Zero3 TBA product could tap into a total addressable market of more than $2.5 billion annually. TriAgenics is already on its way to capitalizing on this opportunity. The company has completed extensive research and development, achieving a 100% success rate in animal trials in preventing wisdom tooth formation. This success has paved the way for the next critical step: obtaining FDA clearance. If approved, TriAgenics plans to begin commercializing Zero3 TBA in 2025, with licensed dentists treating patients. The process will involve dentists sending X-rays and prescriptions to TriAgenics, which will then produce custom 3TBA guides. These guides, designed specifically for each patient, will be sold to dentists at an estimated $350 per tooth bud treated. The company has already raised over $11.5 million in capital, a testament to the investor interest in its technology. Furthermore, TriAgenics has established a robust intellectual property portfolio, securing 32 U.S. and international patents, expanding patent coverage in Australia, Canada, Europe and Mexico. This IP position, combined with growing interest from oral surgeons and pediatric dental specialists, potentially positions TriAgenics as a frontrunner in the future of dental care. Potential To Transform Dental Care As TriAgenics advances toward FDA clearance and market entry, the company could be poised to disrupt the traditional approach to wisdom teeth management. Zero3 TBA offers a solution that could spare tens of millions from the pain, risks and costs associated with wisdom teeth removal. By preventing the formation of wisdom teeth, TriAgenics is not just offering a new product; it’s proposing a paradigm shift in how dental care is approached. “Dental practitioners have expressed tremendous excitement about the potential to eliminate all complications normally associated with wisdom teeth removal,” said Dr. Leigh Colby, TriAgenics CEO. “We believe this will be the industry standard of care by 2030.” The implications of Zero3 TBA extend beyond just a single procedure. If successful, the company believes this technology could set a new standard in preventative dental care, reducing the need for invasive surgeries and the associated complications that may come with them. This means less pain, fewer risks and significant cost savings for patients. For the dental industry, it could represent a major leap forward in how care is delivered. To explore how TriAgenics is shaping the future of wisdom teeth management, check out TriAgenics on StartEngine. Featured photo by S&B Vonlanthen on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 09, 2024 08:35 AM Eastern Daylight Time

Image
Article thumbnail News Release

Bitcoin Miner Bitdeer (NASDAQ: BTDR) Grows Q2 Revenue Amid Volatile Market Backdrop

Benzinga

By Gerelyn Terzo, Benzinga Bitdeer’s R&D run rate continues to hover in the range of $5 million-$6 million as the company moves ahead on the optimization of its SEALMINER technology series and upgrades at its global datacenter facilities. Bitcoin miner Bitdeer Technologies Group (NASDAQ: BTDR), which is behind the SEALMINER application-specific integrated circuit (ASIC) technology, has reported its Q2 2024 financial results. Bitdeer seems to have held its own against a challenging mining backdrop, owing to difficult broader market conditions in the wake of the Bitcoin mining halving event. After reaching an all-time high of over $73,000 in March, the Bitcoin price has pulled back, but remains up 133% over the past 12-month stretch. Bitdeer’s performance seems to be resilient, generating year-over-year growth across its revenue, gross profit and adjusted EBITDA, despite also suffering a net loss. Among the quarterly highlights, the Singapore-based blockchain company’s total revenue came in slightly below $100 million, up roughly 6% compared with year-ago results of $93.8 million. Performance was driven largely by Bitdeer’s self-mining division, the revenue for which nearly doubled to $41.6 million compared with $21.6 million in the year-ago period. Bitdeer’s proprietary self-hosted business mined 628 Bitcoins during the quarter. The company generally sells those Bitcoins for cash shortly after mining them. Self-mining revenue drivers were two-pronged, comprising a soaring self-mining hashrate, which reflects total computing power, to 7.3 EH/s from 3.8 EH/s in its Bhutan mining datacenter as well as a bullish Bitcoin price. The Bhutan facility became operational in H2 2023. Bitdeer’s cloud hash rate revenue declined by a sharp 33% in the quarter, owing to broader market conditions leading to changes in the amount of active orders and a drop in electricity subscriptions amid lower margins caused by the Bitcoin halving event in April. The Bitcoin halving had a domino effect, causing the temporary shutdown of hosting mining rigs and pressuring general hosting revenue. However, it is important to note that any hash rate allocated to cloud mining rolls into self mining when these contracts roll off. Bitdeer remains profitable on an adjusted EBITDA basis, with that metric coming in at $24.9 million and representing a 25% increase compared to year-ago levels. Its Q2 gross profit came in at $24.4 million, ballooning 50% higher compared with $16.2 million in the year-ago period. However, Bitdeer continues to operate at a net loss, which amounted to $17.7 million in the quarter compared with a $40.4 million net loss in the year-ago quarter. The most recent net loss was associated with a non-cash expense of the fair value change for warrants on stablecoin company Tether, with which Bitdeer partnered for a private placement financing earlier this year. Those warrants could still be converted to equity, thereby offsetting any liabilities. Graphic Source: Bitdeer on LinkedIn Bitdeer ended the quarter with nearly $204 million in cash and cash equivalents on the balance sheet, including close to $25 million in cryptocurrency. The company operates in a capex-heavy industry, directing $17.5 million into its products and mining machines during the quarter. As its ASIC chip and machine production continues to ramp up, Bitdeer may be able to offset these investments while continuing to grow revenue. Of the Q2 performance, Bitdeer Chief Business Officer Matt Kong stated, “We achieved these results despite significant growth in the global network hashrate and the April 2024 halving. This demonstrates the strength of our differentiated strategy, underpinned by Bitdeer’s commitment to technology and innovation.” Bitdeer’s Operations And Outlook Bitdeer has several datacenter projects under development across the United States, Norway and Bhutan, all of which the company says remain on track. It has set its sights on expansion and expects these projects will support its growth for the foreseeable future. In its power and data center infrastructure business, Bitdeer signed a 30-year lease agreement for 570 MW of power capacity in Ohio, thereby strengthening its total capacity. Earlier this year, Bitdeer launched a high-performance computing (HPC) and AI business, for which it deployed Nvidia (NASDAQ: NVDA) systems in Singapore and achieved a 100% utilization rate at the start of Q3. During Q2, Bitdeer reports that it advanced its SEALMINER ASIC roadmap, including the recent acquisition of crypto ASIC design company Desiweminer. Bitdeer has deployed its maiden batch of its SEALMINER A1 chips, initiating mass production with a view to add 3.4 EH/s into its data centers by year-end 2024. Bitdeer is awaiting delivery of its second-generation SEAL02 chip products by the end of Q3, after which time it plans to ramp up production for deployment by year-end. Once these chips become available, Bitdeer says it will have the opportunity to generate immediate cash flow from customer pre-orders. Bitdeer On Investor Radars Despite uncertainty around where the Bitcoin price will end in 2024, Bitdeer says it has a robust roadmap, one that involves an ambitious pipeline around its self-mining business, ASIC miner technology, cloud capabilities, AI-powered data centers and more. While Bitdeer’s stock is currently trading below its 52-week high, Wall Street analysts have an average “buy” rating on BTDR shares, suggesting that the stock could have more runway for gains. Investors who are interested in participating in the Bitcoin mining sector can learn more about Bitdeer’s stock here. Featured photo by the-design_org on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 09, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

This New Gamified Trading Platform Is Eyeing A Share Of The $30B-A-Year Fantasy Sports Market

Benzinga

By James Blacker, Benzinga Fantasy sports has developed into a $30 billion-per-year industry, with millions of players around the world drawn to the thrill of the game and the potential to win big rewards. According to Straits Research, the global fantasy sports market was valued at $28.23 billion in 2023 and is estimated to grow at a compound annual growth rate of 14.1% to reach $92.52 billion by 2032. Within this flourishing market, fantasy trading platform BullRush is carving out a space by combining the excitement of fantasy sports with trading in a gamified platform. The Thrill Of Fantasy Trading Traditional fantasy sports platforms involve managing sports teams, such as in the Premier League, NBA or MLB. BullRush is putting its own twist on this idea by making you the manager of your own simulated trading portfolio. While the trades may be simulated, the adrenaline of seeing your portfolio fluctuate is anything but. Traders can play single-round games or bracket-style tournaments, testing their strategies against fellow traders in real-time markets. The top traders in each event earn more than just bragging rights, with cash prizes and other rewards up for grabs – offering an incentive to level up your trading game. While regular fantasy sports sites require successful participants to have an in-depth knowledge of the sport, including its teams and players, BullRush rewards those who excel in market analysis and developing profitable trading strategies. Whether you are a long-time trader or new to the markets, BullRush offers a platform where you can show off your trading skills to the rest of the community. Beyond trading in the markets, BullRush offers various other games to keep players engaged. From testing your skills against the market in the Challenge Arena to flexing your financial knowledge in trivia games, BullRush community members have plenty of different ways to trade, compete and win. A Large Market Opportunity The fantasy sports industry is booming, with one of the biggest platforms, Fantasy Premier League, attracting more than 11 million players. This enormous scale highlights the potential for growth within the market, particularly for innovative platforms like BullRush, which are carving out their own niche within the industry. By tapping into the existing popularity of fantasy sports, BullRush could be well-positioned to attract not only existing fantasy sports fans but also newcomers who are interested in financial markets. With the industry already valued at almost $30 billion per year and growing, BullRush’s platform, which launches officially on September 9, is getting into the industry at the right time. Have You Got What It Takes? Whether you want to improve your trading, share strategies with other traders or simply have fun with trading games and challenges, BullRush has you covered. The company has created a fun, interactive, gamified experience that appeals to a diverse audience of traders and fantasy sports fans alike. Think you’ve got what it takes to take home the prize? Sign up for BullRush’s games here. Featured image courtesy of BullRush. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 09, 2024 08:20 AM Eastern Daylight Time

Image
Article thumbnail News Release

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF): Major Approvals Make TBRIF A Stock To Watch

TBRIF

The medical device sector is experiencing rapid growth, driven by technological advancements and rising global healthcare needs. According to Statista, the global market is set to expand at an annual rate of 5.71%, reaching $673.10 billion by 2029. In 2024 alone, the United States is expected to generate $179.80 billion in medical device revenues, underscoring the sector’s substantial potential. In this burgeoning market, Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) stands out as an emerging leader. The company has made notable progress in diagnostics and health-tech solutions, with recent milestones such as the approval of reimbursement for its Venowave VW5 device. These developments highlight Therma Bright’s strong growth potential and its ability to open new revenue streams in the healthcare and medical technology sectors. Reimbursement Approval: A Game-Changer for Revenue On August 19, 2024, Therma Bright announced a landmark achievement with the U.S. Centers for Medicare and Medicaid Services (CMS) granting permanent Healthcare Common Procedure Coding System (HCPCS) code E0683 to its Venowave VW5 device. This approval signifies a major breakthrough, as it not only provides a specific reimbursement code but also sets a precedent for the device's integration into the U.S. healthcare system. Rob Fia, CEO of Therma Bright, expressed his enthusiasm about the development: "We're pleased that the Centers for Medicare and Medicaid have approved our permanent code request, as well as the reimbursement pricing and the new HCPCS Level II designation for our Venowave VW5 device." This approval ensures that Venowave VW5 will be reimbursed for up to $1,199 per device or $78.05 per month for rental, totaling up to $819.55 over 13 months. The device addresses critical circulatory issues, including deep vein thrombosis (DVT), a condition affecting over 900,000 U.S. citizens annually. The reimbursement approval opens a major revenue channel for Therma Bright. Market research projects that the global market for DVT-related treatments will reach $1.5 billion by 2032. With the Venowave VW5 device being the first of its kind to receive a permanent HCPCS code, Therma Bright is poised to capture a significant share of this expanding market. Strategic Investments and Expanding Market Reach In addition to the reimbursement milestone, Therma Bright has been actively expanding its footprint through strategic investments and partnerships. On August 22, 2024, the company announced the securing of a nationwide U.S. distribution partner for the Venowave VW5. This partner will launch an initial sales program to assess Medicare/Medicaid reimbursement timelines and billing procedures, with a commitment to acquire inventory valued at up to $2.38 million post-program success. The partnership is a testament to the confidence in Venowave’s market readiness and the anticipated success of the reimbursement process. Rob Fia highlighted the significance of this deal: "We are thrilled to welcome our nationwide distribution partner to our team... We expect the program to be successful, leading to a significant increase in Venowave orders on a monthly basis and accelerating our revenue growth." Innovative Technological Advancements Therma Bright’s innovative approach extends beyond Venowave. On August 16, 2024, the company revealed that its AI-powered Digital Cough Technology (DCT) is under consideration for a clinical trial involving a new chronic cough drug. This AI-driven platform aims to enhance data collection and clinical decision-making, showcasing Therma Bright’s commitment to advancing healthcare technology. Additionally, Therma Bright continues to make strategic investments in cutting-edge solutions. On August 6, 2024, the company increased its investment in InStatin, a firm developing an inhaled statin for chronic lung conditions. This move not only boosts Therma Bright’s stake but also positions the company to benefit from potential breakthroughs in asthma and COPD treatments. Leadership and Future Prospects The company’s progress is further supported by recent additions to its advisory board. On August 13, 2024, Therma Bright welcomed Michael Raimondo, a seasoned expert in medical sales and operations, to its advisory board. Raimondo’s extensive experience is expected to drive sales growth and navigate the complexities of U.S. healthcare reimbursement processes. Rob Fia commented on Raimondo’s appointment: "We are pleased that Michael has agreed to join Therma Bright's Advisory Board, where his skills and experience in sales and operations will aid in the company’s sales efforts of its health-tech and med-tech devices." Conclusion Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) is poised for significant growth following the approval of the HCPCS code for its Venowave VW5 device. This milestone opens up opportunities in the large DVT treatment market. With strategic investments, new partnerships, and technological advancements, TBRIF is well-positioned for future success, potentially making it a compelling stock for investors Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and has been compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

September 09, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

EURONAV SHAREHOLDERS IN LINE FOR A US$46 MILLION PAYOUT FOLLOWING COURT RULING AGAINST CMB

FourWorld Capital Management

On Friday, the Brussels Market Court in Belgium ruled that Compagnie Maritime Belge (CMB) wrongly calculated the offer price of shares during its mandatory takeover of Euronav NV in February this year. The court decided the value of each share should be retrospectively increased by at least US$0.52, amounting to an additional pay out of US$46 million. This sum takes into account the 69.2 million shares tendered in March 2024, and those remaining that may be sold if the public offer is re-opened. The Markets’ Court found that when calculating the bid price, CMB had failed to take into account special advantages worth US$104 million granted to Frontline when simultaneously selling it the best part of Euronav’s fleet (its newest 24 VLCC’s or very large crude carriers). The Court’s findings are exceptionally critical of CMB and Frontline: “It is particularly curious that the negotiations regarding the sale of the fleet, although they involved a transaction between Frontline and Euronav, took place exclusively between Frontline and CMB. Euronav was not at the negotiating table. As FourWorld rightly puts it, Euronav was completely sidelined” (para. 112) “CMB and Frontline exerted tremendous pressure on Euronav's supervisory board. (…) The independent chairwoman of the council, in particular, was placed under intense pressure” (para. 115) “Under normal market conditions, transactions are negotiated between directly involved parties, especially between buyer and seller. This is not what happened here. The price of about 2.35 billion dollar paid by Frontline cannot therefore be considered market-conform under these circumstances. This price implied a particular advantage in favor of Frontline.” (para. 117) This ruling breaks new legal ground in Belgium and abroad regarding judicial protection of the minority shareholders, putting brazen bidders willing to game the system on notice. These findings were only made possible after key documents, including supervisory board meeting minutes, legal and financial advice and further evidence, were made available to the public following a court ruling in the United States earlier this year in a case also brought by FourWorld Capital Management LLC (FourWorld). John Addis, Founder and Chief Investment Officer (CIO) of FourWorld said: “Friday’s ruling makes it clear that Euronav’s two largest shareholders acted to serve their own interests at the expense of the company and minority shareholders which is an important first step in unravelling this deal. We believe there was a far greater cost to independent shareholders than recognized by the Brussels Market Court on Friday. “CMB and Frontline managed to pull off the deal of a lifetime underneath the noses of Euronav’s supervisory board and financial regulators. Our years of experience fighting for minority shareholder interests has shown that if a deal looks too good to be true, it probably is. FourWorld will continue to fight through the courts for a fair outcome to this case.” The Brussels Markets’ Court placed the resolution of the share price adjustment firmly back in the jurisdiction of the Belgian financial regulator (FSMA), ordering it to re-examine the bid price taking into account its findings. This means that the FSMA may yet increase the bid price by more than 0,52 US$ – something FourWorld will ask it to do. Having concluded that Euronav’s Supervisory board was sidelined and then coerced, this ruling paves the way for success in a separate legal challenge currently underway in the Antwerp Enterprise Court. In that case, FourWorld has petitioned for the unwinding of CMB’s mandatory takeover, Euronav’s US$2.35 billion fleet sale to Frontline and Euronav’s decision to renounce and settle its arbitration claim against Frontline. The case is scheduled to appear before the Antwerp Enterprise Court in May 2026. - ENDS - Notes for Editors: About FourWorld Capital Management LLC: FourWorld Capital Management is an SEC registered investment adviser with offices in New York and Munich. The company has a particular focus on legal and regulatory catalysts and is currently fighting for a fairer deal on behalf of minority shareholders who lost out during CMB’s mandatory takeover of Euronav NV in 2024 and following its failed merger with Frontline. Contact Information: To request interviews or further information please email: Jenny.wright@highgate.ltd or Theo.Crutcher@highgate.ltd FourWorld Capital Management LLC: FourWorld Capital Management is an SEC registered investment adviser with offices in New York and Munich. The company has a particular focus on legal and regulatory catalysts and is currently fighting for a fairer deal on behalf of minority shareholders who lost out during CMB’s mandatory takeover of Euronav NV in 2024 and following its failed merger with Frontline. Contact Details Highgate Jenny Wright jenny.wright@highgate.ltd Highgate Theo Crutcher theo.crutcher@highgate.ltd Company Website https://www.fourworldcapital.com/

September 09, 2024 12:01 AM Eastern Daylight Time

Article thumbnail News Release

Investments & Wealth Academy Wins “Best in Industry Association” in the WealthManagement.com 2024 Wealthie Awards

Investments & Wealth Institute

Investments & Wealth Institute (“the Institute”), the premier professional membership association, education provider, and credentialing body for financial service professionals and advisors serving high-net-worth clients, has been recognized as the winner of the Industry Association category in the WealthManagement.com 2024 Industry Awards (the "Wealthies") for its premier online learning platform, the Investments & Wealth Academy. This award underscores the Institute’s commitment to continually informing the expertise and strengthening the credentials of those who shape the future of finance. The Institute launched the Academy in November 2023 to enhance the multi-modal educational programs offered by the Institute. Designed to elevate the learning experience for both seasoned and NextGen advisors using universal design best practices, the Academy acts as a one-of-a-kind learning platform that provides access to short-form (on-demand webinars, microcourses, etc.) and long-form (short courses, “best of” bundles, certificate programs, etc.) content. This diversity of offerings helps advisors learn what they want to, when they want to, and how they want to. “We’re honored to receive this prestigious award from WealthManagement.com,” said Sean Walters, CAE ®, CEO of the Institute. “Led by Chief Learning Officer, Ross Riskin, our online education team has built a contemporary learning platform that is truly a “best-in-class” experience. Academy serves advisors of all ages and skill levels who are looking for timely, relevant, academically sound content with practical application.” Now in its 10th year, the WealthManagement.com Industry Awards is the only awards program of its kind to honor outstanding achievements by companies, organizations and individuals that support financial advisor success. "A record-breaking number of nominations were submitted in 2024, with over 1,000 entries received from more than 400 companies," said David Armstrong, Director of Editorial Strategy and Operations, Wealth Management Group – Informa Connect. "The Industry Awards program has significantly expanded in scope in the ten years since it began, but the mission remains the same: To recognize and celebrate the outstanding initiatives undertaken by companies and individuals that contribute to the success of financial advisors in their businesses and foster improved outcomes for their clients." The Institute was selected as the Industry Association winner by a panel of independent judges made up of industry leaders who evaluated finalist initiatives based on quantitative (e.g., scope, scale, adoption, and feature set) and qualitative (innovation, creativity, and new methods of delivery) measures. A complete list of the 2024 Industry Awards winners and finalists can be found here. About WealthManagement.com WealthManagement.com, an Informa business, provides everything wealth professionals need to know to stay knowledgeable about the industry, build stronger relationships, improve their practice, and grow their business. WealthManagement.com offers financial services organizations a broad array of marketing services designed to help them influence the industry’s leading audience of wealth management professionals. About the Investments & Wealth Institute Founded in 1985, the Investments & Wealth Institute is the premier professional association, education provider, and standards body for financial advisors. Through its award-winning events, publications, courses, and acclaimed certifications — Certified Investment Management Analyst® (CIMA®), Certified Private Wealth Advisor® (CPWA®), and Retirement Management Advisor® (RMA®) — the Institute delivers Ivy league-quality, highly practical education to more than 20,000 practitioners annually in over 40 countries. Members of the Institute include the industry's most successful investment consultants, advanced financial planners, and private wealth managers who embrace excellence and ethics in applying a broad set of knowledge and skills in their daily work with clients. Contact Details Allison Edmondson +1 303-850-3207 aedmondson@i-w.org Company Website https://investmentsandwealth.org

September 06, 2024 05:00 PM Eastern Daylight Time

Image
Article thumbnail News Release

Historic First Sports Event at The Coca-Cola Music Hall Set for Friday, October 18

21 Events, Inc.

Puerto Rico’s premier entertainment destination, the iconic Coca-Cola Music Hall, will make history as it hosts its first-ever boxing event on Friday, October 18, as Salita Promotions presents “Big Time Boxing – Puerto Rico”. In collaboration with PR Best Boxing Promotions (PRBBP) and 21 Events, this exciting professional fight card will be streamed live and worldwide on DAZN, the global leader in world championship boxing. As part of a dynamic collaboration between Salita Promotions and PR Best Boxing Promotions and 21 Events in Puerto Rico, this event is part of Salita Promotions’ renowned “Big Time Boxing USA” series, the leading developmental series for promising prospects and young contenders on their journey toward a world championship. “Puerto Rico has been the cradle of boxing greatness for generations, producing some of the greatest stars the sport has ever seen,” said Dmitriy Salita, president of Salita Promotions. “I am excited to partner with PR Best and 21 Events to develop and discover the next superstars ready to emerge from this great island.” The fight card, featuring up to eight (8) exciting matches, will be revealed in the coming days. All sports and boxing fans should stay tuned for more event information, which will soon be available on www.ticketera.com and the venue’s official website, www.cocacolamusichall.com. Since opening its doors in 2021, the Coca-Cola Music Hall – managed by ASM Global and located in the heart of DISTRITO T-Mobile – has become a world-class venue, hosting top Latin American and international artists. Therefore, on October 18, history will be made with the first-ever boxing event at this important venue. “We are honored to host our first boxing event at the Coca-Cola Music Hall. This historic event highlights the versatility of our venue, proving it can accommodate a diverse array of events. We are ready to welcome the fans for what will undoubtedly be a memorable night”, stated Jorge L. Pérez, Regional General Manager of ASM Global in Puerto Rico. “Just as it was 20 years ago when we held the first boxing event in the then new Coliseo de Puerto Rico José Miguel Agrelot, now we are presenting the first sports event in the great Coca-Cola Music Hall with Salita Promotions and 21 Events”, stated Iván Rivera, president of PRBBP. “We are happy to work with the Coca-Cola Music Hall and the Puerto Rico Convention Center District Authority team to make history again with this event”. “We at the PRCCDA are proud to present Championship Boxing at the Coca-Cola Music Hall for the first time ever and to promote Puerto Rico worldwide via the DAZN streaming network”, stated Mariela Vallines, Executive Director of the PRCCDA. ABOUT PRCCDA Puerto Rico Convention Center District Authority (PRCCDA) is a public corporation created under Law Number 351 of September 2nd of 2000, as amended. Its mission is to develop and operate the Convention District, positioning Puerto Rico as a world-class business, tourism, and entertainment destination. PRCCDA’s objectives include efficiently managing prominent venues, revitalizing urban areas, promoting job creation and business opportunities, and acting as a facilitator in partnership with the private sector. ABOUT SALITA PROMOTIONS Salita Promotions was founded in 2010 by Dmitriy Salita, a professional boxer and world-title challenger who saw the need for a promotional entity to feature boxing’s best young prospects and established contenders in North America and around the world. Viewers watching fighters on worldwide television networks including SHOWTIME, HBO, ESPN, Spike TV, Universal Sports Network, UFC Fight Pass, DAZN, ESPN+ and MSG have enjoyed Salita Promotions fight action in recent years. We pride ourselves on offering our fighters opportunities inside and outside the ring. Salita Promotions looks forward to continuing to grow and serve the needs of fight fans around the globe. ABOUT PR BEST BOXING PR Best Boxing Promotions was founded in February 2001 by Peter and Ivan Rivera with its first boxing show being on May 20 of that same year, broadcasted live internationally on the Telefutura network. PRBBP has worked and developed great Puerto Rican world champions such as Hall of Famers Miguel Cotto and Iván Calderón as well as Román “Rocky” Martínez, Eric Morel and Juan Manuel “Juanma” López among others. Considered the best boxing promotion company in Puerto Rico, PRBBP has presented boxing cards broadcast by the best TV networks such as ESPN, Univision, Showtime, Telefutura, HBO and PPV events. PRBBP presented the first boxing event broadcast live on the ESPN network from Puerto Rico, also the first boxing broadcast by the PPV system from the Island and presented the first sports event at the Coliseo de Puerto Rico José Miguel Agrelot. ABOUT 21 EVENTS 21 Events, a fully integrated Latino marketing firm with 20 years of experience in producing marketing solutions and events in Sports and Entertainment that drive measurable results for our fortune 500 clients seeking true engagement with Latino consumers. ABOUT COCA-COLA MUSIC HALL The Coca-Cola Music Hall (CCMH) is a property managed by ASM Global, located at 250 Convention Boulevard, San Juan, Puerto Rico. It was developed by PRISA Group and its construction was completed in 2020. Naming rights were sold to The Coca-Cola Company in 2019. This venue is known for being a modern, hip, and state-of-the-art facility that incorporates artistic and cultural elements characteristic of Puerto Rico. The property features three levels and can accommodate up to 4,000 people seated. Contact Details PR Best Boxing Iván Rivera, President +1 787-406-7219 PRBestBoxingPrensa@gmail.com PR Best Boxing Aleudi Rosario Cotto, PR +1 787-645-1132 PRBestBoxingPrensa@gmail.com Salita Promotions Chris DeBlasio Cdeblasio99@gmail.com

September 06, 2024 03:56 PM Eastern Daylight Time

Image
Article thumbnail News Release

Syntekabio to Highlight its Cutting-edge AI-driven Discovery Solutions at BioTechX

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, today announced its participation at BioTechX USA, being held September 17-18, 2024 in Philadelphia, PA. Syntekabio is the Title Sponsor for the event and will give a keynote address and in-depth talk on its AI-driven solutions, as well as host a booth. “We look forward to meeting with potential clients at BioTechX and discussing how our AI-driven technologies can improve and accelerate their R&D activities,” said Jongsun Jung, PhD, CEO of Syntekabio. “We recently announced our ‘Develop Now, Pay Later’ offer that enables clients to test the validity of a target protein of interest without incurring any upfront costs. In addition to identifying potential hits and optimizing small molecule leads, we also have strong capabilities in antibody and cancer neoantigen discovery. We are excited to have the opportunity to highlight these technologies at the conference.” Meet us at BioTechX USA! Syntekabio has several activities planned at the conference. Schedule a meeting by clicking here or stop by our booth (#401) to meet the team and learn how our innovative AI-driven solutions can help solve your current pipeline challenges. Don’t miss out on the latest insights in AI presented in our talks! Tuesday, September 17 th 9:20 AM - Keynote presentation Addressing Data Scarcity in D rug Discovery with Physics-based AI Models Jonathan Witztum, PhD, CTO, Syntekabio USA 5:05 PM – AI in drug discovery presentation Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application Jongsun Jung, PhD, CEO, Syntekabio Recently announced Develop Now, Pay Later offer – drug discovery with no upfront fees Syntekabio’s Develop Now, Pay Later model enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs. Should a project demonstrate viability, Syntekabio then employs its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher ® technology platform, to deliver hits and optimized leads as well as IND-enabled candidates. The client only pays for the work once the agreed upon validated results are obtained. For more information about Syntekabio, STB LaunchPad and Develop Now, Pay Later, please click here. Additional powerful tools enable novel antibody and cancer neoantigen prediction Additionally, the company will highlight its in silico biologics platforms, Neo-ARS TM and Ab-ARS TM, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively. These cutting-edge solutions address complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics. Syntekabio’s AI accesses over 10 billion known compounds as well as 1,400 in vitro/in vivo compatible drug targets covering over 70% of human diseases. This technology is powered by Syntekabio’s AI Bio-Supercom Center, which houses an immense infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs fueling the Company’s algorithms. The Company has a comprehensive suite of advanced proprietary tools designed to accelerate the drug discovery and development process. About Syntekabio Syntekabio Co., Ltd. (KOSDAQ: 226330) is a ​drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results.​ Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase.​ The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries US & Europe - MC Services AG Laurie Doyle / Dr. Cora Kaiser +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 06, 2024 08:30 AM Eastern Daylight Time

1 ... 6465666768 ... 3772